|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.7 EUR | -1.29% |
|
+1.76% | -2.30% |
| Apr. 24 | SANOFI : Bernstein remains its Buy rating | ZD |
| Apr. 24 | Sanofi to Enlist Banks for $20 Billion Consumer-health Spinoff | MT |
By Cecilia Butini
Sanofi SA said Thursday that the European Union gave marketing authorization to a drug it developed to treat hemolytic anemia in adult patients with cold agglutinin disease, an autommune disease targeting red blood cells.
The French pharma company said that its drug, a monoclonal antibody named Enjaymo, is currently the only approved treatment for the disease.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
11-17-22 1314ET
| 1st Jan change | Capi. | |
|---|---|---|
| -2.30% | 119B | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
SANOFI 
